👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Advanced Proteome Therapeutics Corp (APCh)

CBOE Canada
Currency in CAD
0.040
+0.030(+300.00%)
Closed
APCh Scorecard
Full Analysis
Significant return over the last week
Fair Value
Day's Range
0.0350.040
52 wk Range
0.0050.055
Bid/Ask
0.005 / 0.015
Prev. Close
0.01
Open
0.035
Day's Range
0.035-0.04
52 wk Range
0.005-0.055
Volume
16,000
Average Volume (3m)
23,142
1-Year Change
33.33%
Fair Value
Unlock
Fair Value Upside
Unlock
APCh Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Advanced Proteome Therapeutics Corp Company Profile

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.

Sector
Financial
Employees
0
Market
Canada

Compare APCh to Peers and Sector

Metrics to compare
APCh
Peers
Sector
Relationship
P/E Ratio
0.0x−6.6x0.0x
PEG Ratio
0.00−0.140.00
Price/Book
0.0x2.2x1.6x
Price / LTM Sales
0.0x0.0x1.2x
Upside (Analyst Target)
0.0%130.1%25.8%
Fair Value Upside
Unlock−8.0%1.1%Unlock

FAQ

What Is the Advanced Proteome (APCh) Stock Price Today?

The Advanced Proteome stock price today is 0.04

What Stock Exchange Does Advanced Proteome Trade On?

Advanced Proteome is listed and trades on the CBOE Canada stock exchange.

What Is the Stock Symbol for Advanced Proteome?

The stock symbol for Advanced Proteome is "APCh."

What Is the Advanced Proteome Market Cap?

As of today, Advanced Proteome market cap is 2.70M.

What is Advanced Proteome Earnings Per Share?

The Advanced Proteome EPS is 0.03.

From a Technical Analysis Perspective, Is APCh a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.